Quantitation of alprazolam and α-hydroxyalprazolam in human plasma using liquid chromatography electrospray ionization MS-MS

Journal of Analytical Toxicology

Volumn 23, Issue 6, 1999, Pages 479-485

  Crouch, Dennis J ^a   Rollins, Douglas E ^a   Canfield, Dennis V ^b   Andrenyak, David M ^a   Schulties, Janie E ^a  

^a UNIVERSITY OF UTAH   (United States)

^b CIVIL AEROSPACE MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYALPRAZOLAM; ALPRAZOLAM; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HYDROLYSIS; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SCREENING; ORAL DRUG ADMINISTRATION; PH;

EID: 0032850607     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/23.6.479     Document Type: Article

References (30)

1. H. Schütz. Benzodiazepines II. Springer-Verlag, Berlin, Germany, 1989.
2. J.G. Hardman, A. Goodman. Gilman, and L.E. Limbird. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. McGraw-Hill, 1996.
3. J. Becker, A. Correll, W. Koepf, and C. Rittner. Comparative studies on the detection of benzodiazepines in serum by means of immunoassays (FPIA). J. Anal. Toxicol. 17: 103-108 (1993).
4. A.D. Fraser. Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT® d.a.u.™ Benzodiazepine metabolite assay. J. Anal. Toxicol. 11: 263-266 (1987).
5. A.D. Fraser, W. Bryan, and A.F. Isner. Urinary screening for α-OH triazolam by FPIA and EIA with confirmation by GC/MS. J. Anal. Toxicol. 16: 347-350 (1992).
6. W. Huang, D.E. Moody, D.M. Andrenyak, and D.E. Rollins. Immunoassay detection of nordiazepam, triazolam, lorazepam, and alprazolam in blood J. Anal. Toxicol. 17: 365-369 (1993).
7. E.S. Burstein, H. Freidman, D.J. Greenblatt, A. Locniskar, and H.R. Ochs. Quantitation of flurazepam and three metabolites by electron capture gas liquid chromatography. J. Anal. Toxicol. 12: 122-125 (1988).
8. H. Gjerde, E. Dahlin, and A.S. Christopherson. Simultaneous determination of common benzodiazepines in blood using capillary gas chromatography. J. Pharm. Biomed. Anal. 10(5): 317-322 (1992).
9. I. Klebovich, M. Kapas, and L. Vereczkey. A rapid capillary gas chromatographic method for the determination of diazepam in human plasma and saliva. Acta Pharm. Hung. 2: 246-252 (1982).
10. D.J. Greenblatt, J.I. Javaid, A. Locniskar, J.S. Harmatz, and R.I. Shader. Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. J. Chromatogr. 534: 202-207 (1990).
11. H. Maurer and K. Pfleger. Identification and differentiation of benzodiazepines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J. Chromatogr. 422: 85-101 (1987).
12. P. Kintz and P. Mangin. Plasma determination of flumazenil, a benzodiazepine antagonist, by immunotoxicology and by capillary gas chromatography/mass spectrometry. J. Anal. Toxicol. 15: 202-203 (1991).
13. D.A. Black, G.D. Clark, V.M. Haver, J.A. Garbin, and A.J. Saxon. Analysis of urinary benzodiazepines using solid-phase extraction and gas chromatography-mass spectrometry. J. Anal. Toxicol. 18: 185-188 (1994).
14. W.A. Joern. Confirmation of low concentrations of urinary benzodiazepines, including alprazolam and triazolam, by GC/MS: an extractive alkylation procedure. J. Anal. Toxicol. 16: 363-367 (1992).
15. R.L. Fitzgerald, D.A. Rexin, and D.A. Herold. Benzodiazepine analysis by negative chemical ionization gas chromatography/mass spectrometry. J. Anal. Toxicol. 17: 342-347 (1993).
16. E.M. Koves and B. Yen. The use of gas chromatography/negative ion chemical ionization mass spectrometry for determination of lorazepam in whole blood. J. Anal. Toxicol. 13: 69-72 (1989).
17. E.R. Cairns, B.R. Dent, J.C. Ouwerkerk, and L.J. Porter. Quantitative analysis of alprazolam and triazolam in hemolysed whole blood and liver digest by GC/MS/NICI with deuterated internal standards. J. Anal. Toxicol. 18: 1-6 (1994).
18. K.M. Höld, D.J. Crouch, D.E. Rollins, D.C. Wilkins, D.V. Canfield, and R.A. Maes. Determination of alprazolam and α-hydroxyalprazolam in human plasma by gas chromatography/negative-ion chemical ionization mass spectrometry. J. Mass Spectrom. 31: 1033-1038 (1996).
19. I.M. McIntyre, M.L. Syrjanen, K. Crump, S. Horomidis, A.W. Peace, and O.H. Drummer. Simultaneous HPLC gradient analysis of 15 benzodiazepines and selected metabolites in postmortem blood. J. Anal. Toxicol. 17: 202-207 (1993).
20. V.D. Schmith, S.R. Cox, M.A. Zemaitis, and P.D. Kroboth. New high-performance liquid chromatographic method for the determination of alprazolam and its metabolites in serum: instability of 4-hydroxyalprazolam. J. Chromatogr. 568: 253-260 (1991).
21. L. Jin and C.E. Lau. Determination of alprazolam and its major metabolites in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. J. Chromatogr. B 654: 77-83 (1994).
22. W.E. Lambert, E. Meyer, Y. Xue-Ping, and A.P. De Leenheer. Screening, identification, and quantitation of benzodiazepines in postmortem samples by HPLC with photodiode array detection. J. Anal. Toxicol. 19: 35-40 (1995).
23. M. Kleinschnitz, M. Herderich, and P. Schreier. Determination of 1,4-benzodiazepines by high-performance liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B 676: 61-67 (1996).
24. D.J. Crouch, M.E. Alburgues, A.C, Spanbauer, D.E. Rollins, D.M. Moody, and A.A. Chasin, Analysis of cocaine and its metabolites from biological specimens by solid phase extraction and chemical ionization mass spectrometry. J. Anal. Toxicol. 19: 352-358 (1995).
25. A. Bond, J.C. Silveira, and M. Lader. Effects of single doses of alprazolam and alcohol alone and in combination on psychological performance. Hum. Psychopharmacol. 6: 219-228 (1991).
26. M. Burns and H. Moskowitz. Alcohol, marihuana and skills performance. In Alcohol, Drugs and Traffic Safety, Vol. 3. Stockholm, Sweden, 1980, pp 954-968.
27. D. Greenblatt and C.E. Wright. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin. Pharmacokinet. 24(6): 453-471 (1993).
28. D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, D.A. Ciraulo, and R.I. Shader. Alprazolam pharmacokinetics, metabolism, and plasma levels: Clinical implications. J. Clin. Psychiatry 54(10 suppl): 4-14 (1993).
29. D.J. Greenblatt, J.S. Harmatz, and R.I. Shader. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. Arch. Gen. Psychiatry 50: 715-722 (1993).
30. M. Widman, S. Agurell, M. Ehmebo, and G. Jones. Binding of (+/-) and (-)-delta-one-tetrahydrocannabinol and (-)-7-hydroxy-delta-one-tetrahydrocannabinol to blood cell and plasma proteins in man. J. Pharm. Pharmacol. 26: 914-916 (1974).